lorlatinib
1 clinical trial
5 products
16 abstracts
1 indication
Indication
Advanced CancersAbstract
Lorlatinib vs crizotinib in treatment-naïve patients with advanced ALK+ non-small cell lung cancer: 5-year progression-free survival and safety from the CROWN study.Org: Pfizer Inc., European Institute of Oncology IRCCS, National Cancer Center Hospital East, Kashiwa, Japan, Guangdong Lung Cancer Institute, Tennessee Oncology, PLLC,
Abstract
Impact of molecular therapy on radioactive iodine uptake in patients with oncogene-driven metastatic differentiated thyroid cancer.Org: Division of Endocrinology and Diabetes, The Thyroid Center,
Abstract
Immune infiltrate characterization and differential gene expression by RNA-sequencing analysis in patients with oncogene-addicted NSCLC with early progression under targeted therapy.Org: Genomic Platform and Biobank, AMMICa UAR3655/US23, Gustave Roussy, Cancer Campus,
Abstract
Global retrospective study comparing consolidation ALK tyrosine kinase inhibitors (TKI) to durvalumab (durva) or observation (obs) after chemoradiation (CRT) in unresectable locally-advanced ALK+ non-small cell lung cancer (NSCLC).Org: Yale New Haven Hospital, Yale Cancer Center, Yale School of Medicine, New Haven, CT, Princess Margaret Cancer Centre, University Health Network, Massachusetts General Hospital,
Abstract
Timing of EGFR or ALK inhibitor initiation and survival among patients with advanced NSCLC.Org: Department of Thoracic Oncology, Kanagawa Cancer Center, H. Lee Moffitt Cancer Center and Research Institute,
Abstract
Lorlatinib in TKI naïve, advanced ROS1-positive non-small-cell lung cancer: A multicenter, open-label, single-arm, phase 2 trial.Org: Center for Lung Cancer, Division of Hematology and Oncology, Department of Internal Medicine, China Medical University Hospital, Taichung, Taiwan, Department of Internal Medicine C, University Hospital Greifswald, Greifswald, Germany, Research Institute and Hospital, National Cancer Center Hospital East, Kashiwa, Japan,
Abstract
Implementing personalized lung cancer care with spatial profiling, patient derived organoids, and rationally designed drug testing.Org: University of Colorado Anschutz Medical Campus, University of Colorado Cancer Center, University of Colorado School of Medicine, Veterans Affairs Medical Center, University of Colorado Denver Anschutz Medical Center,
Abstract
Novel LTK fusions based on NGS sequencing data in Chinese patients with solid tumors.Org: Shanghai OrigiMed Co., Ltd., Shanghai, China,
Abstract
Management of patients with ALK-positive advanced non-small cell lung cancer who received brain radiotherapy on study in the phase 3 CROWN trial.Org: Sarah Cannon Research Institute/Tennessee Oncology, Tennessee Oncology, PLLC, Vall d’Hebron University Hospital/VHIO, Vall d’Hebron Institute of Oncology (VHIO), State Key Laboratory of South China,
Abstract
A first-in-human, phase 1 study of the SHP2 inhibitor PF-07284892 as monotherapy and in combination with different targeted therapies in oncogene-driven, treatment-resistant solid tumors.Org: Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College University, The Sarah Cannon Research Institute, Division of Hematology/Oncology, Henry Ford Health System, Pfizer, Inc.,
Abstract
Mechanisms of resistance to tyrosine kinase inhibitor treatments in patients with ROS1 fusion-positive non-small cell lung cancer.Org: Department of Thoracic Medical Oncology, Hunan Cancer Hospital, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China, Fudan University Shanghai Cancer Center, Geneseeq Research Institute, Nanjing Geneseeq Technology Inc.,
Abstract
First-in-human, multicenter phase Ⅰ study of TGRX-326 in patients with advanced ALK-positive non-small cell lung cancer.Org: Sun Yat-sen University Cancer Center Gansu Hospital, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China, Collaborative Innovation Center for Cancer Medicine, Hunan Cancer Hospital/the Affiliated Cancer Hospital of Xiangya School of Medicine, Changsha, China, Guangzhou JOYO Pharma,
Abstract
Differentiating ensartinib from lorlatinib and alectinib for first line use in an ALK+ non-small cell lung cancer preclinical model (ResCu).Org: resistanceBio, San Carlos, CA,
Abstract
A real-world study of ALK fusion detection, treatment patterns, and survival outcomes of patients with advanced non–small-cell lung cancer (aNSCLC) in Brazil.Org: Oncoclinicas & Co - Medica Scientia Innovation Research (MEDSIR), Rio De Janeiro, Brazil, Oncoclinícas, Oncoclínicas Bahia, Hospital Santa Izabel,
Product
Various ALK inhibitorsProduct
targeted therapiesProduct
ALK TKIsProduct
ALK-TKIProduct
lorlatinibClinical trial
A PHASE 1 STUDY TO EVALUATE THE EFFECT OF HEPATIC IMPAIRMENT ON THE PHARMACOKINETICS AND SAFETY OF LORLATINIB IN ADVANCED CANCER PATIENTSStatus: Terminated, Estimated PCD: 2021-07-08